Get the Stockscreener App
22.28
3.00%
-0.69
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $22.28, with a volume of 38.96M.
It is down -3.00% in the last 24 hours and down -0.93% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$22.97
Open:
$22.51
24h Volume:
38.96M
Relative Volume:
0.81
Market Cap:
$137.59B
Revenue:
$62.46B
Net Income/Loss:
$7.88B
P/E Ratio:
16.14
EPS:
1.38
Net Cash Flow:
$11.22B
1W Performance:
-7.93%
1M Performance:
-0.93%
6M Performance:
-16.62%
1Y Performance:
-20.94%
1-Day Range:
$22.26
$22.60
1-Week Range:
$22.26
$24.25
52-Week Range:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
22.28 | 137.59B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
734.57 | 739.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.22 | 375.64B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
184.60 | 351.09B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
65.77 | 307.32B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
108.70 | 225.73B | 53.22B | 12.86B | 14.85B | 6.39 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer’s $15 Billion War Chest: What Will They Buy After the Danuglipron Failure? - Smartkarma
Is Pfizer Inc. (PFE) the Best High-Yield Dividend Stock for 2025 and Beyond? - Yahoo Finance
Pfizer (NYSE:PFE) Hasn't Been This Cheap in 13 Years. Time to Buy? - 24/7 Wall St.
Pfizer (PFE) Just Overtook the 20-Day Moving Average - Yahoo Finance
Was Jim Cramer Right About Pfizer (PFE)? - Yahoo Finance
Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment - Endpoints News
If You Invested $10K In Pfizer Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Chronic Pelvic Pain Treatment Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Johnson & Johnson, AbbVie Inc. - openPR.com
Pfizer Sues Alkem to Block Copies of Xeljanz XR Arthritis Drug - Bloomberg Law News
Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Pfizer Inc. (NYSE:PFE) Q1 2025 Earnings Call Transcript - MSN
The Mindfulness of Medicine Development: How Scientists Are Driving the Next Wave of Medical Innovations - Pfizer
Jim Cramer on Pfizer (PFE): “Trying Big Targets, but New Wins Still Elusive” - Insider Monkey
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 - marketscreener.com
Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments - GlobeNewswire Inc.
Pfizer (PFE) Awaits FDA Panel Review of Cancer Drug Combination - GuruFocus
Pfizer, J&J, Genentech drugs subject of FDA advisory panel meeting this month - Seeking Alpha
Ex-Dividend Reminder: American Electric Power, Pfizer and Tompkins Financial - Nasdaq
Pharma imports to US surged in March as drugmakers look to avoid tariffs - marketscreener.com
Trump Sets Pharma Tariffs Deadline. The Fallout for Lilly, Pfizer, Other Drugmakers. - Barron's
Pfizer (PFE) RSV Vaccine Recommendations Under Review - GuruFocus
Pfizer, GSK RSV shot recommendations under scrutiny from RFK Jr. aidereport - Seeking Alpha
PFE Stock Price: Pfizer Inc Named Top Dividend Stock as Insider Buying Surges, Yield Hits 7.21% - paginasiete.bo
Pfizer Has Unreasonable Whiff Of The Marlboro Man - Seeking Alpha
Pfizer Named Top Dividend Stock With Insider Buying and 7.21% Yield (PFE) - Nasdaq
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics - TradingView
Here's Why We're Wary Of Buying Pfizer's (NYSE:PFE) For Its Upcoming Dividend - simplywall.st
Do These 3 Checks Before Buying Pfizer Inc. (NYSE:PFE) For Its Upcoming Dividend - Yahoo Finance
Recombinant Human Endostatin Market Top PlayersPfizer Inc., - openPR.com
Pfizer Stock Up 5% Following Q1 Results: Time To Buy, Sell Or Hold? - Barchart.com
Analyst recommendations: Amazon, PepsiCo, Linde, Pfizer, Crowdstrike Holdings... - marketscreener.com
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Sirolimus Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Actiza, Zydus Cadila Healthcare Ltd. - openPR.com
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold? - Yahoo Finance
Anti Suicide Drugs Market Detailed In New Research Report 2025 | - openPR.com
Is Pfizer Inc. (PFE) The Most Profitable Cheap Stock to Buy Now? - Insider Monkey
Is Pfizer Inc.'s (NYSE:PFE) Stock Price Struggling As A Result Of Its Mixed Financials? - Yahoo Finance
West Virginia counties, cities to receive Pfizer settlement checks - WBOY.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025) - 24/7 Wall St.
Drug Discovery Market Is Booming So Rapidly 2025-2032Pfizer - openPR.com
Pfizer Inc (PFE-N) Stock Price and News - The Globe and Mail
Do Wall Street Analysts Like Pfizer Stock? - Nasdaq
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Zacks.com featured highlights Centene, Pediatrix Medical, Pfizer, StoneCo and Banco Santander - Nasdaq
Pfizer donates $250K to Oklahoma Tribal health clinics - The Journal Record
What's Next For Pfizer Stock After A Mixed Q1? - Nasdaq
Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive - Law360
Pfizer CEO Tariff Uncertainty Hinders U.S. Investments - MSN
Pfizer CEO Albert Bourla Emphasizes National Security In US Drug Manufacturing - Benzinga
Pfizer (NYSE:PFE) Reports Q1 Earnings, Reaffirms 2025 Revenue Guidance at US$61-64 Billion - Yahoo Finance
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):